Valion Bio annual gross margin
2021
2022
2023
2024
Valion Bio's gross margin was 0.26% for fiscal 2024.
View full Valion Bio company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | 0.26% | −24.15 pp |
| 2023 | 2023-12-31 | 24.40% | +8.15 pp |
| 2022 | 2022-12-31 | 16.25% | +19.27 pp |
| 2021 | 2021-12-31 | −3.02% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-09-30 | −99.32% | −134.24 pp |
| Q2 2025 | 2025-06-30 | 62.79% | +41.36 pp |
| Q1 2025 | 2025-03-31 | 71.43% | +21.43 pp |
| Q4 2024 | 2024-12-31 | −132.78% | −134.18 pp |
| Q3 2024 | 2024-09-30 | 34.92% | −3.38 pp |
| Q2 2024 | 2024-06-30 | 21.43% | −16.46 pp |
| Q1 2024 | 2024-03-31 | 50.00% | +19.95 pp |
| Q4 2023 | 2023-12-31 | 1.40% | −8.67 pp |
| Q3 2023 | 2023-09-30 | 38.30% | +25.09 pp |
| Q2 2023 | 2023-06-30 | 37.89% | +14.21 pp |
| Q1 2023 | 2023-03-31 | 30.05% | +13.70 pp |
| Q4 2022 | 2022-12-31 | 10.07% | +10.33 pp |
| Q3 2022 | 2022-09-30 | 13.21% | +22.59 pp |
| Q2 2022 | 2022-06-30 | 23.67% | +35.99 pp |
| Q1 2022 | 2022-03-31 | 16.36% | +9.54 pp |
| Q4 2021 | 2021-12-31 | −0.26% | — |
| Q3 2021 | 2021-09-30 | −9.39% | — |
| Q2 2021 | 2021-06-30 | −12.31% | — |
| Q1 2021 | 2021-03-31 | 6.81% | — |
Across the available reported history, Valion Bio's gross margin decreased from 24.40% to 0.26%, a change of −24.15 percentage points. The latest reported quarter, Q3 2025, shows −99.32%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Valion Bio filings at SEC.gov ↗